The approval and success of powerful new cancer treatments such as CAR T-cell therapy are breeding optimism among companies, scientists and patients around the world.TD2 can help influence your trial design and get your drug on a faster path to approval.
September 30, 2020
- Fc Receptors (FcR) and their Relevance to Flow Cytometry
- Large Panel Design to Identify Human and Mouse Lymphocyte Subsets Using Cytek® Aurora Flow Cytometers
- Featured Guest Blog: Cardiac Stem Cells by Darcey L. Clark
- The Technology Behind Spectral Flow Cytometry
- Outrunning Resistance: Why Preclinical Insight Is the Key to Durable Oncology Therapies
Fc Receptors (FcR) and their Relevance to Flow Cytometry
By Jennifer J. Stewart PhD
Large Panel Design to Identify Human and Mouse Lymphocyte Subsets Using Cytek® Aurora Flow Cytometers
By Duangchan Suwannasaen PhD, Scientist
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
